November 20, 2025
7:00pm – 8:00pm
Repatha (evolocumab): Clinical outcomes in Cardiovascular Disease Part 2
Describe the role of evolocumab, a PCSK9 inhibitor, in reduction of major cardiovascular outcomes in the ASCVD population, as well as those patients who are at high-risk for an event. This will include new late-breaking data from the VESALIUS study that was recently presented at the American Heart Association conference.
Speaker: Sarah Zukkoor Zorn, PharmD, BCPS
Senior Medical Science Liaison | Cardiovascular
Amgen US Medical
Attendance is not required; there is no fee to participate; and no CE is offered for this sponsored education program. Contact Megan with questions.
Link to join the webinar:
Join Zoom Meeting
https://us02web.zoom.us/j/83273817813?pwd=vE5OuqbzyWnEn7rqeuaZqjfgLbvDq6.1
Meeting ID: 832 7381 7813
Passcode: 967172
—
One tap mobile
+13126266799,,83273817813#,,,,*967172# US (Chicago)
The link to participate in the Amgen webinar will also be added to chat during the first program.